Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
771.76-
QQQ
718.390.1%
BTC/USD
79560.002.1114%
DIA
535.600.25%
GLD
402.851.8%
TLT
82.170.12%

Elicio Therapeutics Inc

ELTXNASDAQ
Trade with Public
Trade with Public
$2.50
-0.05-1.96%
At close: Sep 2, 5:00 PM EST
$2.50
-0.05-1.96%
Pre-Market: 4:00 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Elicio Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Elicio Therapeutics (ELTX).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

4Buy
1Hold
Consensus RatingBuy# Analysts5Avg. Consensus PT$18Upside to Avg. PT+620.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 18, 2026HC Wainwright & Co.Robert BurnsMaintainedBuy$23
Jun 18, 2026Ladenburg ThalmannKevin DeGeeterAssumesBuy$12
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $23 price target.
Benzinga Newsdesk

PRO
Ladenburg Thalmann Assumes Elicio Therapeutics at Buy, Announces Price Target of $12

Ladenburg Thalmann analyst Kevin DeGeeter assumes Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $12.
Benzinga Newsdesk

PRO
Jones Trading Downgrades Elicio Therapeutics to Hold

Jones Trading analyst Boris Peaker downgrades Elicio Therapeutics (NASDAQ:ELTX) from Buy to Hold.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $23

HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and raises the price target from $17 to $23.
Benzinga Newsdesk

PRO
B. Riley Securities Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $27

B. Riley Securities analyst Mayank Mamtani initiates coverage on Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $27.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $17 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $17 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved